Date: November 2, 2022
Time: 5:30 - 8:30 pm MST
Location: Hacienda del Sol, 5501 Hacienda Del Sol Road, Tucson, AZ 85718
SNMMI has applied for 2 hours of CE Credit for this in-person event.
Please note that seating is limited and registration will be available on a first-come, first-served basis.
Dinner is Served
Several new radiopharmaceuticals are now being used in both large academic and small practice settings to stage and identify local and metastatic prostate cancer, including the recently approved Ga-68 PSMA-11 and 18F-DCFPyL. In addition, the FDA in March approved Lu 177 vipivotide tetraxetan to treat PSMA-positive metastatic castration-resistant prostate cancer. Given these new advancements in diagnosis and treatment, how does one navigate the changing landscape to provide the best outcomes for the patient?
6:30 - 6:35 pm
Welcome and Introductions
Bital Savir-Baruch, MD
6:35 - 6:55 pm
State of PSMA Imaging and Therapy: Nuclear Medicine Perspective
Bital Savir-Baruch, MD, University of Arizona College of Medicine
6:55 - 7:15 pm
Urology Perspective - Detection and Management of Primary and Early Recurrence Prostate Cancer
Juan Chipollini, MD, University of Arizona College of Medicine
7:15 - 7:35 pm
Radiation Oncology Perspective - Management of Oligometastatic Disease
Shona Dougherty, MD, University of Arizona College of Medicine
7:35 - 7:55 pm
Hematology/Oncology Perspective - Standard of Practice of Metastatic Prostate Cancer (HS and CRPC)
Edward Gelmann, MD, University of Arizona College of Medicine
7:55 - 8:15 pm
Clinical Oncology Perspective - Case-Based and Practice Clinical Dilemmas
Alejandro Recio Boiles, MD, University of Arizona College of Medicine
8:15 - 8:30 pm
Q&A and Panel Discussion
Please note: SNMMI is committed to ensuring that appropriate and necessary health and safety protocols will be in place for this event. We will follow all Centers for Disease Control and Prevention (CDC) safety protocols and recommendations and will comply with all federal, state, and local regulations in force at the time of the event.
CE Credit applications for physicians, pharmacists, and technologists (AMA PRA, VOICE, and ACPE credits) are pending. Check back for updates regarding CE Credit status.
This event is supported through a medical education grant from Novartis Pharmaceuticals Corporation.